Select Bibliography

Filter by any of these (after searching):

Rubenstein, J. L.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

Rubenstein, J. L. , Hsi, E. D. , Johnson, J. L. , Jung, S.-H. ... - ASH - ASH Annual Meeting Abstracts - 2012

Abstract - Secondary - Primary - Lymphoma - CALGB-50202

Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

Rubenstein, J. L. , Hsi, E. D. , Johnson, J. L. , Jung, S.-H. ... - - J Clin Oncol - 2013

Manuscript - Primary - Primary - Lymphoma - CALGB-50202

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

Rubenstein, J. L. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - ASH - Blood - 2010

Abstract - Primary - Primary - Lymphoma - CALGB-50202